Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15698069 | 0.81 | HSP90AB1 (0.42) | GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL9532477 | 0.81 | GSK3B (0.32) | GSK3BGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL22359915 | 0.78 | GSK3B (0.48) | GSK3BPTPN1GAAMEN1KMT2A | |
| SCHEMBL9278783 | 0.78 | MAPT (0.38) | MEN1KMT2AALDH1A1 | |
| SCHEMBL28256316 | 0.77 | LMNA (0.41) | GSK3BMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL865601 | 0.76 | MEN1 (0.36) | GSK3BMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL7787256 | 0.75 | KMT2A (0.37) | GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL11364813 | 0.74 | GSK3B (0.43) | GSK3BPTPN1 | |
| SCHEMBL11956604 | 0.74 | GSK3B (0.54) | GSK3BPTPN1MEN1KMT2AALDH1A1 | |
| SCHEMBL7528224 | 0.73 | GSK3B (0.39) | GSK3BPTPN1HPGDSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009416-A1 | THIAZOLIUM COMPOUNDS AND USES THEREOF | MYCOSOL, INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009416-A1 | THIAZOLIUM COMPOUNDS AND USES THEREOF | TST, TYR, THOP1 | GSK3B 1848/4885PTPN1 834/4885HPGDS 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.